Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.
The companies are competing in the weight loss drug market.
Eli Lilly (LLY) and Novo Nordisk (NVO) are both major players in the pharmaceutical industry, with a significant focus on weight loss drugs. Novo Nordisk entered the market first, while Eli Lilly followed shortly after. Both companies produce tirzepatide (Mounjaro for diabetes and Zepbound for weight loss) and semaglutide (Ozempic for diabetes and Wegovy for weight loss). These GLP-1 drugs have led to a surge in revenue and increased stock prices for both companies.
However, Eli Lilly has emerged as the dominant force, with its market capitalization nearly nine times that of Novo Nordisk. This gap can be attributed to Lilly's aggressive manufacturing efforts and the superior weight loss results of its tirzepatide compared to Novo Nordisk's semaglutide. Despite Wegovy (Novo Nordisk's weight loss pill) currently holding a larger share of prescriptions, Lilly's Foundayo is gaining ground, and the future looks promising for the weight loss-focused pharma giant.
Despite some challenges Novo Nordisk has faced, investors are still drawn to Lilly's growth potential, particularly with its new oral weight loss drug, Foundayo.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
